1-7 of 7
Julien Taieb
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

Claire Gallois, Matteo Landi, Julien Taieb, Marine Sroussi, Bahar Saberzadeh-Ardestani, Antoine Cazelles, Sara Lonardi, Francesca Bergamo, Rossana Intini, Giulia Maddalena, Filippo Pietrantonio, Francesca Corti, Margherita Ambrosini, Antonia Martinetti, Marco Maria Germani, Chiara Boccaccio, Guglielmo Vetere, Sophie Mouillet-Richard, Aurélien de Reynies, Frank A. Sinicrope, Chiara Cremolini, Pierre Laurent-Puig
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3771–3778.
https://doi.org/10.1158/1078-0432.CCR-22-3964
Published: 15 September 2023
View article titled, Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Open the PDF for Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial

Julien Taieb, Valérie Taly, Julie Henriques, Camille Bourreau, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Christophe Louvet, Céline Lepere, May Mabro, Joëlle Egreteau, Olivier Bouche, Claire Mulot, Katia Hormigos, Kariman Chaba, Thibault Mazard, Aimery de Gramont, Dewi Vernerey, Thierry André, Pierre Laurent-Puig
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5638–5646.
https://doi.org/10.1158/1078-0432.CCR-21-0271
Published: 15 October 2021
View article titled, Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a <em>Post Hoc</em> Analysis of the PRODIGE-GERCOR IDEA-France Trial
Open the PDF for Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a <em>Post Hoc</em> Analysis of the PRODIGE-GERCOR IDEA-France Trial in another window
Includes: Supplementary data
Journal Articles

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

Laetitia Marisa, Yuna Blum, Julien Taieb, Mira Ayadi, Camilla Pilati, Karine Le Malicot, Côme Lepage, Ramon Salazar, Daniela Aust, Alex Duval, Hélène Blons, Valérie Taly, David Gentien, Audrey Rapinat, Janick Selves, Sophie Mouillet-Richard, Valérie Boige, Jean-François Emile, Aurélien de Reyniès, Pierre Laurent-Puig
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4768–4780.
https://doi.org/10.1158/1078-0432.CCR-21-0529
Published: 01 September 2021
View article titled, Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
Open the PDF for Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer in another window
Includes: Supplementary data
Journal Articles

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy

Claire Gallois, Julien Taieb, Delphine Le Corre, Karine Le Malicot, Josep Tabernero, Claire Mulot, Jean-François Seitz, Thomas Aparicio, Gunnar Folprecht, Côme Lepage, Enrico Mini, Jean-Luc Van Laethem, Jean-François Emile, Pierre Laurent-Puig
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4745–4753.
https://doi.org/10.1158/1078-0432.CCR-18-0866
Published: 01 October 2018
View article titled, Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
Open the PDF for Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)

Fanny Garlan, Pierre Laurent-Puig, David Sefrioui, Nathalie Siauve, Audrey Didelot, Nasrin Sarafan-Vasseur, Pierre Michel, Geraldine Perkins, Claire Mulot, Hélène Blons, Julien Taieb, Frederic Di Fiore, Valerie Taly, Aziz Zaanan
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5416–5425.
https://doi.org/10.1158/1078-0432.CCR-16-3155
Published: 14 September 2017
View article titled, Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
Open the PDF for Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study) in another window
Includes: Supplementary data
Journal Articles

Colon Cancer Mutation: Prognosis/Prediction–Letter

Aziz Zaanan, Franck Bonnetain, Franck A. Sinicrope, Pierre Laurent-Puig, Julien Taïeb
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1300.
https://doi.org/10.1158/1078-0432.CCR-12-3765
Published: 03 March 2013
View article titled, Colon Cancer Mutation: Prognosis/Prediction–Letter
Open the PDF for Colon Cancer Mutation: Prognosis/Prediction–Letter in another window
Journal Articles

Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy

Aziz Zaanan, Jean-François Fléjou, Jean-François Emile, Guetz Gaëtan Des, Peggy Cuilliere-Dartigues, David Malka, Cédric Lecaille, Pierre Validire, Christophe Louvet, Philippe Rougier, Aimery de Gramont, Franck Bonnetain, Françoise Praz, Julien Taïeb
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7470–7478.
https://doi.org/10.1158/1078-0432.CCR-11-1048
Published: 30 November 2011
View article titled, Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
Open the PDF for Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy in another window
Includes: Supplementary data